secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001193125-24-144956
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics secures $200M immediate funding from Royalty Pharma; restructures aficamten royalty
--------------------------------------------------------------------------------

- Received $50M upfront from Tranche 6 term loan and $100M from 2024 DFA; plus $50M from CK-586 RPA; total $200M immediate cash.
- Aficamten royalty restructured: RPI gets 4.5% up to $5B net sales (was $1B), then 1% above $5B (was 3.5%).
- Optional $175M Tranche 7 term loan if FDA approves aficamten for HCM by Dec 31, 2025; repayment at 190% of principal.
- CK-586 RPA provides up to $200M total; RPI funds 50% of R&D costs after Phase 3 start; receives 1-4.5% royalty plus milestone payments.
- Stock Purchase Agreement allows Cytokinetics to require RPI to buy $50M shares in next equity financing (min $250M gross) by Aug 20, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312524144956/0001193125-24-144956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312524144956/d796481d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-144956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer